Abstract
Since 1992, the United States has relied heavily on the pharmaceutical industry to pay the salaries of FDA scientists who review new drug applications. Dr. Jerry Avorn writes that most federal regulatory agencies do not derive such a large proportion of their operating budgets from the industries they oversee.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
